Giulia Carreras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giulia Carreras has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Adriana Albini
Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy
1 shared publication- Alessio Lachi
Saint Camillus International University of Health and Medical Sciences, Rome, Italy
1 shared publication Andrea Saltelli
UPF Barcelona School of Management, Pompeu Fabra University, Barcelona, Spain
1 shared publicationAurora Gaeta
Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
1 shared publicationCalogero Saieva
Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
1 shared publicationCecilia Viscardi
Department of Economics and Statistics, University of Salerno, Fisciano, Italy
1 shared publication
Latest Publications
- 18 March 2026
- Published by BMJ in Tobacco Control
What is the best tobacco control policy in Tuscany? An assessment using uncertainty analysis
Introduction Cigarette smoking continues to exert a major impact on morbidity and mortality. We aim to provide robust estimates of smoking dynamics and their effects on mortality in Tuscany, Italy, from 1993 to 2019, along with forecasts under alternative tobacco control policies (TCPs). Methods Smoking dynamics are modelled using a compartmental model combined with Monte Carlo (MC) simulations to propagate uncertainties. A variance-based global sensitivity analysis (GSA) quantifies the contribution of each input to output variance. TCPs are ranked according to the Surface Under the Cumulative Ranking Curve (SUCRA). Results The MC approach produces results consistent with those obtained when only sampling variability is considered, although with wider uncertainty intervals (UIs). We estimate that in 2023 smoking caused 3,348 deaths (90% UI 2,761 to 3,942) among men and 1749 deaths (90% UI 1,397 to 2,888) among women aged over 65. By 2063, these numbers are projected to decline to 1477 (90% UI 1,081 to 2,144) and 1,436 (90% UI 742 to 2,138), respectively. According to the GSA, the time period used for calibrating the model is the main source of uncertainty in the model outputs, suggesting that the phenomenon has changed over time. The tobacco-free generation policy (TCP1) shows the highest SUCRA for smoking prevalence, while cessation treatments rank highest for mortality impact. Discussion The approach shows promise for identifying key sources of uncertainty and guiding public health strategies. Although uncertainty limits the precise quantification of future dynamics and impacts, the TCP1 is likely to exert the strongest long-term effect on reducing smoking prevalence, while cessation interventions remain essential for achieving short-term reductions in smoking-attributable mortality.
- 18 March 2026
- Published by BMJ in Tobacco Control
What is the best tobacco control policy in Tuscany? An assessment using uncertainty analysis
Introduction Cigarette smoking continues to exert a major impact on morbidity and mortality. We aim to provide robust estimates of smoking dynamics and their effects on mortality in Tuscany, Italy, from 1993 to 2019, along with forecasts under alternative tobacco control policies (TCPs). Methods Smoking dynamics are modelled using a compartmental model combined with Monte Carlo (MC) simulations to propagate uncertainties. A variance-based global sensitivity analysis (GSA) quantifies the contribution of each input to output variance. TCPs are ranked according to the Surface Under the Cumulative Ranking Curve (SUCRA). Results The MC approach produces results consistent with those obtained when only sampling variability is considered, although with wider uncertainty intervals (UIs). We estimate that in 2023 smoking caused 3,348 deaths (90% UI 2,761 to 3,942) among men and 1749 deaths (90% UI 1,397 to 2,888) among women aged over 65. By 2063, these numbers are projected to decline to 1477 (90% UI 1,081 to 2,144) and 1,436 (90% UI 742 to 2,138), respectively. According to the GSA, the time period used for calibrating the model is the main source of uncertainty in the model outputs, suggesting that the phenomenon has changed over time. The tobacco-free generation policy (TCP1) shows the highest SUCRA for smoking prevalence, while cessation treatments rank highest for mortality impact. Discussion The approach shows promise for identifying key sources of uncertainty and guiding public health strategies. Although uncertainty limits the precise quantification of future dynamics and impacts, the TCP1 is likely to exert the strongest long-term effect on reducing smoking prevalence, while cessation interventions remain essential for achieving short-term reductions in smoking-attributable mortality.
- 6 January 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (2) , 240-249
Upgrading your best chances: postdiagnosis smoking cessation boosts life expectancy of patients with cancer – a systematic review and meta-analysis
Background: Tobacco use is linked to increased cancer risk, and people who smoke represent a large proportion of newly diagnosed patients with cancer. The fact that smoking cessation at the time of diagnosis can improve the patient’s life expectancy is still not broadly understood. We conducted a systematic review and meta-analysis to quantify the survival benefits obtainable by quitting smoking on diagnosis. We included articles found in MEDLINE and EMBASE until 2 January 2024. We conducted a random effects meta-analysis, studying correlates of between-studies heterogeneity and exploring the presence of publication bias. There were 36 eligible studies published in 1980–2023, totalling over 17 000 actively smoking patients with cancer. The most studied cancer sites were the lung (n=17) and head and neck (n=14). The median proportion of patients who quit on diagnosis was 42.5%. Postdiagnosis cessation was associated with longer overall survival (summary HR (sHR) 0.71, 95% CI 0.65 to 0.78), progression-free survival (sHR 0.64, 95% CI 0.41 to 0.98), disease-free/recurrence-free survival (sHR 0.59, 95% CI 0.43 to 0.81) and improved local/locoregional control (sHR 0.69, 95% CI 0.50 to 0.94). Heterogeneity was generally large; for overall survival, study results were stronger when properly adjusted but did not vary across cancer sites. There was evidence for publication bias, but the results were only marginally altered on imputation of potentially missing studies. Postdiagnosis smoking cessation is effective in improving the chances of survival for patients with cancer. Cessation support programmes should be integrated into the routine management of patients with cancer as they may favourably affect survival.
- 6 January 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (2) , 240-249
Upgrading your best chances: postdiagnosis smoking cessation boosts life expectancy of patients with cancer – a systematic review and meta-analysis
Background: Tobacco use is linked to increased cancer risk, and people who smoke represent a large proportion of newly diagnosed patients with cancer. The fact that smoking cessation at the time of diagnosis can improve the patient’s life expectancy is still not broadly understood. We conducted a systematic review and meta-analysis to quantify the survival benefits obtainable by quitting smoking on diagnosis. We included articles found in MEDLINE and EMBASE until 2 January 2024. We conducted a random effects meta-analysis, studying correlates of between-studies heterogeneity and exploring the presence of publication bias. There were 36 eligible studies published in 1980–2023, totalling over 17 000 actively smoking patients with cancer. The most studied cancer sites were the lung (n=17) and head and neck (n=14). The median proportion of patients who quit on diagnosis was 42.5%. Postdiagnosis cessation was associated with longer overall survival (summary HR (sHR) 0.71, 95% CI 0.65 to 0.78), progression-free survival (sHR 0.64, 95% CI 0.41 to 0.98), disease-free/recurrence-free survival (sHR 0.59, 95% CI 0.43 to 0.81) and improved local/locoregional control (sHR 0.69, 95% CI 0.50 to 0.94). Heterogeneity was generally large; for overall survival, study results were stronger when properly adjusted but did not vary across cancer sites. There was evidence for publication bias, but the results were only marginally altered on imputation of potentially missing studies. Postdiagnosis smoking cessation is effective in improving the chances of survival for patients with cancer. Cessation support programmes should be integrated into the routine management of patients with cancer as they may favourably affect survival.